Neradecast
Cross-source consensus on Neradecast from 1 sources and 3 claims.
1 sources · 3 claims
Uses
Comparisons
Background
Highlighted claims
- Neradecast received FDA approval as an IPF treatment. — IPF as a Fibrotic Disease and Modern Treatment Approaches
- Neradecast was the first new IPF therapy to receive FDA approval in over a decade. — IPF as a Fibrotic Disease and Modern Treatment Approaches
- Neradecast represents a more recent therapeutic advance beyond pirfenidone and nintedanib in the IPF treatment timeline. — IPF as a Fibrotic Disease and Modern Treatment Approaches